Tetrahydro-furan-2-carboxylic acid cyclohexylamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢呋喃
• 英文名称: Tetrahydro-furan-2-carboxylic acid cyclohexylamide
• 英文别名: N-cyclohexyloxolane-2-carboxamide
• 化学式: C₁₁H₁₉NO₂
• mdl: MFCD03377328
• 分子量: 197.277
• InChiKey: OPLNXLOCXAKJRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,3-二氢呋喃 、 异氰环已烷 在 camphor-10-sulfonic acid 作用下， 以 二氯甲烷 为溶剂， 以60%的产率得到Tetrahydro-furan-2-carboxylic acid cyclohexylamide
  参考文献：
  名称：

  Straightforward α-carbamoylation of NADH-like dihydropyridines and enol ethers

  摘要：

  The protonation of NADH-like dihydropyridines and cyclic enol ethers generates reactive cationic intermediates, which interact with isocyanides to afford alpha-carbamoylated heterocycles after an aqueous quenching, in Ugi and Passerini-type reactions, thus broadening the scope of these multicomponent processes. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.08.145

文献信息

• [EN] INHIBITORS OF INFLUENZA VIRUSES REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DES VIRUS DE LA GRIPPE
  申请人：VERTEX PHARMA

  公开号：WO2010148197A1

  公开（公告）日：2010-12-23

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者中流感病毒复制的方法，减少生物样本或患者中流感病毒数量的方法，以及治疗患者流感的方法，包括向所述生物样本或患者中投与有效量的化合物，该化合物由结构式（I）表示或其药学上可接受的盐，其中结构式（IA）的值如此处所述。该化合物由结构式（IA）表示或其药学上可接受的盐，其中结构式（IA）的值如此处所述。一种药物组合物包括有效量的该化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或溶剂。
• INHIBITORS OF INFLUENZA VIRUSES REPLICATION
  申请人：Vertex Pharmaceuticals Inc.

  公开号：EP3141252A1

  公开（公告）日：2017-03-15

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者体内流感病毒复制、减少生物样本或患者体内流感病毒数量以及治疗患者流感的方法，包括向所述生物样本或患者施用有效量的结构式（I）所代表的化合物： 或其药学上可接受的盐，其中结构式（IA）的值如本文所述。一种化合物由结构式（IA）或其药学上可接受的盐代表，其中结构式（IA）的值如本文所述。药物组合物包含有效量的此类化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或载体。
• Visible Light‐promoted C(sp3)‐H α‐Carbamoylation of Cyclic Ethers with Isocyanides
  作者：Camilla Russo、Carmine Volpe、Federica Santoro、Diego Brancaccio、Anna Di Porzio、Alfonso Carotenuto、Antonio Randazzo、Laurence Grimaud、Maxime R. Vitale、Stefano Protti、Mariateresa Giustiniano

  DOI：10.1002/chem.202401997

  日期：2024.8.27

  C(sp3)-H carbamoylation of cyclic ethers has been achieved via a domino sequence of Hydrogen Atom Transfer/Radical Polar Crossover pathways, finally enabling the nucleophilic addition of isocyanides to oxocarbenium ions. The current method features mild reaction conditions to generate oxocarbenium ions from non-activated ethers, along with good substrate scope and functional group compatibility.

  环醚的C( sp 3 )-H氨基甲酰化通过氢原子转移/自由基极性交叉途径的多米诺序列实现，最终实现异氰化物与氧碳鎓离子的亲核加成。目前的方法具有从非活化醚生成氧碳鎓离子的温和反应条件，以及良好的底物范围和官能团兼容性。